Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-124 in Healthy Adults
NCT07377396Phase 1Recruiting
- Sponsor
- argenx
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune disease comparing ARGX-124 with Placebo (2 arms). Primary endpoint: Incidence of Adverse Events, Serious Adverse Events and Adverse Events leading to ARGX-124 discontinuation at 23 weeks. Started Jan 2026; status: recruiting.
02
Drugs
ARGX-124
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT07377396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377396.